A/Prof Emma Link
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
76 Scholarly works
0 Projects
HIGHLIGHTS
2026
Journal article
Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.
DOI: 10.1016/S1470-2045(26)00120-82026
Journal article
The utility of genomics and functional imaging to predict sunitinib pharmacokinetics and pharmacodynamics: The predict SU study
DOI: 10.1002/bcp.704312026
Journal article
Baseline Nodal Status on 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography in Men with Intermediate- to High-risk Prostate Cancer Is Prognostic for Treatment Failure: Follow-up of the proPSMA Trial
DOI: 10.1016/j.euo.2024.11.0062025
Other
Supplementary Data DS1 from A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
DOI: 10.1158/1078-0432.307075642025
Journal article
The Ave–Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
DOI: 10.1158/1078-0432.CCR-25-07052024
Journal article
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma
DOI: 10.1111/bju.161902024
Journal article
UNICAB: Cabozantinib in locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or in those unsuitable for immunotherapy (ANZUP 1802)
DOI: 10.1200/JCO.2024.42.4_suppl.428
RECENT SCHOLARLY WORKS
2023
Journal article
A phase 1 clinical trial of the repurposable acetyllysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma
DOI: 10.1186/s13148-023-01427-72023
Conference Proceedings
The Ave-Rec trial: Phase II trial of PD-L1/PD-1 blockade with avelumab plus chemoradiotherapy for locally advanced resectable T3B-4/N1-2 rectal cancer-Toxicity and interim efficacy data
DOI: 10.1200/jco.2023.41.16_suppl.36162023
Other
Supplementary Data DS1 from A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
DOI: 10.1158/1078-0432.22490194.v1